Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
- Published In:
- Obstetrics and gynecology, 134(5), 899-908 (2019)
- Authors:
- Kingsberg, Sheryl A, Clayton, Anita H, Portman, David, Williams, Laura A, Krop, Julie, Jordan, Robert, Lucas, Johna, Simon, James A
- Database ID:
- RPEP-04281
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04281APA
Kingsberg, Sheryl A; Clayton, Anita H; Portman, David; Williams, Laura A; Krop, Julie; Jordan, Robert; Lucas, Johna; Simon, James A. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.. Obstetrics and gynecology, 134(5), 899-908. https://doi.org/10.1097/AOG.0000000000003500
MLA
Kingsberg, Sheryl A, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.." Obstetrics and gynecology, 2019. https://doi.org/10.1097/AOG.0000000000003500
RethinkPeptides
RethinkPeptides Research Database. "Bremelanotide for the Treatment of Hypoactive Sexual Desire ..." RPEP-04281. Retrieved from https://rethinkpeptides.com/research/kingsberg-2019-bremelanotide-for-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.